July 28th, 2014
This week’s topics include a comparison of catheter-directed thrombolysis plus anticoagulation and anticoagulation alone to treat DVT, several papers on dabigatran and bleeding risk, and more.
November 5th, 2012
Another HDL-raising CETP inhibitor has failed to demonstrate cardiovascular benefit in a large clinical trial. With the presentation of the dal-OUTCOMES trial at the American Heart Association in Los Angeles and simultaneous publication in the New England Journal of Medicine, dalcetrapib joins torceptrapib on the list of once-promising CETP inhibitors. In dal-OUTCOMES, 15,871 patients with a recent […]
May 7th, 2012
Roche announced today that it has ended development of dalcetrapib, its entry into the once-promising class of HDL-raising CETP inhibitors. A data and safety monitoring board recommended that the dal-OUTCOMES phase 3 trial be stopped due to a lack of clinically meaningful efficacy. The DSMB found no evidence of safety problems.
November 16th, 2011
Impressive safety and efficacy data on evacetrapib—but it’s too early give odds on whether it’s a true wonder drug or a nightmare like its fellow CETP inhibitor, torceptrapib
July 18th, 2011
A new analysis of the ILLUMINATE trial raises the possibility that CETP inhibitors like torcetrapib might have the unexpected beneficial effect of improving glycemic control in addition to their intended effect of raising HDL cholesterol. Development of torcetrapib was halted several years ago following the early termination of the large ILLUMINATE trial due to an […]
November 17th, 2010
Following the failure of torcetrapib in 2006, the future of cholesteryl ester transfer protein (CETP) inhibitors appeared quite troubled. Now, with the results of DEFINE (Determining the Efficacy and Tolerability of CETP Inhibition with Anacetrapib), presented at the AHA in Chicago and published online in the New England Journal of Medicine, the future for this novel […]